{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:15:07Z","timestamp":1760865307624},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1999,2,1]],"date-time":"1999-02-01T00:00:00Z","timestamp":917827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[1999,2]]},"DOI":"10.1007\/s11908-999-0014-6","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T01:59:00Z","timestamp":1180058340000},"page":"80-88","source":"Crossref","is-referenced-by-count":14,"title":["Recent developments in epidemiology, treatment, and diagnosis of tuberculosis"],"prefix":"10.1007","volume":"1","author":[{"given":"Carol Dukes","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"14_CR1","unstructured":"Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 1997. MMWR CDC Surveill Summ 1998, 1\u201384. This annual, authoritative report of tuberculosis statistics gives all the facts as well as an easy-to-understand executive summary of trends."},{"key":"14_CR2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1126\/science.257.5073.1055","volume":"257","author":"BR Bloom","year":"1992","unstructured":"Bloom BR, Murray CJL. Tuberculosis: commentary on a reemergent killer. Science 1992, 257:1055\u20131064.","journal-title":"Science"},{"key":"14_CR3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.279.12.943","volume":"279","author":"CP Chaulk","year":"1998","unstructured":"Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998, 279:943\u2013948.","journal-title":"JAMA"},{"key":"14_CR4","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1164\/ajrccm.156.5.9704105","volume":"56","author":"DR Leff","year":"1997","unstructured":"Leff DR, Leff AR: Tuberculosis control policies in major metropolitan health departments in the United States. VI. Standard of Practice in 1996. Am J Respir Crit Care Med 1997, 56:1487\u20131494.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2105\/AJPH.88.7.1059","volume":"88","author":"MT McKenna","year":"1998","unstructured":"McKenna MT, McCray E, Jones JL, Onorato IM, Castro KG. The fall after the rise: Tuberculosis in the United States, 1991 through 1994. Am J Public Health 1998, 88:1059\u20131063.","journal-title":"Am J Public Health"},{"key":"14_CR6","first-page":"1","volume":"44","author":"Centers for Disease Control and Prevention","year":"1995","unstructured":"Centers for Disease Control and Prevention. Essential components of a tuberculosis prevention and control program. MMWR 1995, 44:1\u201334.7.","journal-title":"MMWR"},{"key":"14_CR7","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/archinte.158.13.1440","volume":"158","author":"LP Manangan","year":"1998","unstructured":"Manangan LP, Simonds DN, Pugliese G, et al.: Are US hospitals making progress in implementing guidelines for prevention of Mycobacterium tuberculosis transmission? Arch Intern Med 1998, 158:1440\u20131444.","journal-title":"Arch Intern Med"},{"key":"14_CR8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00003","volume":"129","author":"AL French","year":"1998","unstructured":"French AL, Welbel SF, Dietrich SE, et al.: Use of DNA fingerprinting to assess tuberculosis infection control. Ann Intern Med 1998, 129:856\u2013861.","journal-title":"Ann Intern Med"},{"key":"14_CR9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJM199803053381002","volume":"338","author":"R Bellamy","year":"1998","unstructured":"Bellamy R, Ruwende C, Corrah T et al.: Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998, 338:640\u2013644. This is an important report of translational research investigating the human relevance of a gene identified in mice that appears to encode for mycobacterial resistance or susceptibility phenotype.","journal-title":"N Engl J Med"},{"key":"14_CR10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199803053381008","volume":"338","author":"BR Bloom","year":"1998","unstructured":"Bloom BR, Small PM: The evolving relation between humans and Mycobacterium tuberculosis. N Engl J Med 1998, 338:677\u2013678.","journal-title":"N Engl J Med"},{"key":"14_CR11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1164\/ajrccm.157.4.9704036","volume":"157","author":"MF Cantwell","year":"1998","unstructured":"Cantwell MF, McKenna MT, McCray E, Onorato IM: Tuberculosis and race\/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1998, 157:1016\u20131020. The authors carefully examine and define the attributable risk for tuberculosis by several social economic status indicators. Their finding demonstrates that tuberculosis is another \u201curban health penalty\u201d of impoverishment (see accompanying editorial), but also demonstrates that genetics plays a role in the disproportionate burden of illness in certain racial groups.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR12","first-page":"31","volume":"1","author":"NW Schluger","year":"1997","unstructured":"Schluger NW, Huberman R, Wolinsky N, et al.: Tuberculosis infection and disease among persons seeking social services in New York City. Int J Tuberc Lung Dis 1997, 1:31\u201337.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14_CR13","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1164\/ajrccm.157.4.9708058","volume":"157","author":"KC Cummings","year":"1998","unstructured":"Cummings KC, Mohle-Boetani J, Royce SE, Chin DP: Movement of tuberculosis patients and the failure to complete anti-tuberculosis treatment. Am J Respir Crit Care Med 1998, 157:1249\u20131252.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/jama.1997.03550100064040","volume":"278","author":"L Singleton","year":"1997","unstructured":"Singleton L, Turner M, Haskal R, et al.: Long-term hospitalization for tuberculosis control. Experience with a medical-psychosocial inpatient unit. JAMA 1997, 278:838\u2013842.","journal-title":"JAMA"},{"key":"14_CR15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1164\/ajrccm.157.4.9709071","volume":"57","author":"S Asch","year":"1998","unstructured":"Asch S, Leake B, Anderson R, Gelberg L: Why do symptomatic patients delay obtaining care for tuberculosis? Am J Respir Crit Care Med 1998, 57:1244\u20131248.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1086\/516065","volume":"25","author":"F March","year":"1997","unstructured":"March F, Garriga X, Rodriguez P, et al.: Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin Infect Dis 1997, 25:1044\u20131047.","journal-title":"Clin Infect Dis"},{"key":"14_CR17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/106002809603000901","volume":"30","author":"CA Peloquin","year":"1996","unstructured":"Peloquin CA, Nitta AT, Burman WJ, et al.: Low anti-tuberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996, 30:919\u2013925.","journal-title":"Ann Pharmacother"},{"key":"14_CR18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1086\/514513","volume":"25","author":"SH Choudhri","year":"1997","unstructured":"Choudhri SH, Hawken M, Gathua S, et al.: Pharmacokinetics of anti-mycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 1997, 25:104\u2013111.","journal-title":"Clin Infect Dis"},{"key":"14_CR19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-127-4-199708150-00006","volume":"127","author":"J Sahai","year":"1997","unstructured":"Sahai J, Gallicano K, Swick L, et al.: Reduced plasma concentrations of anti-tuberculosis drugs in patients with HIV infection. Ann Intern Med 1997, 127:289\u2013293.","journal-title":"Ann Intern Med"},{"key":"14_CR20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.1997.03550100059039","volume":"278","author":"M Moore","year":"1997","unstructured":"Moore M, Onorato IM, McCray E, Castro KG: Trends in drug-resistant tuberculosis in the United States, 1993\u20131996. JAMA 1997, 278:833\u2013837.","journal-title":"JAMA"},{"key":"14_CR21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0022-2143(97)90123-2","volume":"130","author":"JJ Ellner","year":"1997","unstructured":"Ellner JJ: Regulation of the human immune response during tuberculosis. J Lab Clin Med 1997, 130:469\u2013475.","journal-title":"J Lab Clin Med"},{"key":"14_CR22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1164\/ajrccm.157.3.9708002","volume":"157","author":"NW Schluger","year":"1998","unstructured":"Schluger NW, Rom WN: The host immune response to tuberculosis. Am J Respir Crit Care Med 1998, 157:679\u2013691. This is an excellent, detailed, and well-referenced review of what is known about the balance between the microbe and the human immune response.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1086\/515276","volume":"177","author":"D Goletti","year":"1998","unstructured":"Goletti D, Weissman D, Jackson RW, et al.: The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. J Infect Dis 1998, 177:1332\u20131338.","journal-title":"J Infect Dis"},{"key":"14_CR24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/0003-4819-127-1-199707010-00006","volume":"127","author":"TA Kenyon","year":"1997","unstructured":"Kenyon TA, Ridzon R, Luskin-Hawk R, et al.: A nosocomial outbreak of multidrug-resistant tuberculosis. Ann Intern Med 1997, 127:32\u201336.","journal-title":"Ann Intern Med"},{"key":"14_CR25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1086\/514546","volume":"25","author":"DC Perlman","year":"1997","unstructured":"Perlman DC, el-Sadr WM, Nelson ET, et al.: Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 1997, 25:242\u2013246.","journal-title":"Clin Infect Dis"},{"key":"14_CR26","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1164\/ajrccm\/146.6.1623","volume":"146","author":"American Thoracic Society","year":"1992","unstructured":"American Thoracic Society: Control of tuberculosis in the United States. Am Rev Respir Dis 1992, 146:1623\u20131633.","journal-title":"Am Rev Respir Dis"},{"key":"14_CR27","first-page":"1","volume":"42","author":"Centers for Disease Control and Prevention","year":"1993","unstructured":"Centers for Disease Control and Prevention: Tuberculosis control laws \u2014 United States, 1993. MMWR 1993, 42:1\u201328.","journal-title":"MMWR"},{"key":"14_CR28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0954-6111(93)90140-U","volume":"87","author":"LP Ormerod","year":"1993","unstructured":"Ormerod LP: Results of tuberculosis contact tracing: Blackburn 1982\u201390. Respir Med 1993, 87:127\u2013131.","journal-title":"Respir Med"},{"key":"14_CR29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/ajrccm.158.2.9801062","volume":"158","author":"MA Behr","year":"1998","unstructured":"Behr MA, Hopewell PC, Paz EA, et al.: Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med 1998, 158:465\u2013469.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR30","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1164\/ajrccm.158.6.9804029","volume":"158","author":"DP Chin","year":"1998","unstructured":"Chin DP, DeRiemer K, Small PM, et al.: Differences in contributing factors to tuberculosis incidence in U.S.-born and foreign-born persons. Am J Respir Crit Care Med 1998, 158:1797\u20131803.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR31","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.280.19.1679","volume":"280","author":"WR Bishai","year":"1998","unstructured":"Bishai WR, Graham NMH, Harrington S, et al.: Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA 1998, 280:1679\u20131684. These articles [29-31] provide insight into ways in which new molecular techniques can be used to inform and improve public health efforts for contact tracing.","journal-title":"JAMA"},{"key":"14_CR32","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJM199406163302402","volume":"330","author":"PM Small","year":"1994","unstructured":"Small PM, Hopewell PC, Singh SP, et al.: The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994, 330:1703\u20131709.","journal-title":"N Engl J Med"},{"key":"14_CR33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJM199406163302403","volume":"330","author":"D Alland","year":"1994","unstructured":"Alland D, Kalkut GE, Moss AR, et al.: Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994, 330:1710\u20131716.","journal-title":"N Engl J Med"},{"key":"14_CR34","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM199406163302410","volume":"330","author":"MA Hamburg","year":"1994","unstructured":"Hamburg MA, Frieden TR: Tuberculosis transmission in the 1990s. N Engl J Med 1994, 330:1750\u20131751.","journal-title":"N Engl J Med"},{"key":"14_CR35","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1086\/515550","volume":"25","author":"MA Behr","year":"1997","unstructured":"Behr MA, Small PM: Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician? Clin Infect Dis 1997, 25:806\u2013810. The article is a good review of molecular techniques and how clinicians may use them to their patient\u2019s benefit.","journal-title":"Clin Infect Dis"},{"key":"14_CR36","first-page":"16","volume":"2","author":"DL Cohn","year":"1998","unstructured":"Cohn DL, O\u2019Brien RJ: The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tuberc Lung Dis 1998, 2:16\u201326.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14_CR37","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJM199504203321606","volume":"332","author":"MT McKenna","year":"1995","unstructured":"McKenna MT, McCray E, Onorato I: The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to \u20131993. N Engl J Med 1995, 332:1071\u20131076.","journal-title":"N Engl J Med"},{"key":"14_CR38","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jama.1997.03550040060038","volume":"278","author":"PLF Zuber","year":"1997","unstructured":"Zuber PLF, McKenna MT, Binkin NJ, et al.: Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997, 278:304\u2013307.","journal-title":"JAMA"},{"key":"14_CR39","first-page":"1","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","unstructured":"Centers for Disease Control and Prevention: Recommendations for prevention and control of tuberculosis among foreign-born persons. Report of the Working Group on Tuberculosis Among Foreign-born Persons. MMWR 1998, 47:1\u201330.","journal-title":"MMWR"},{"key":"14_CR40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJM199803053381001","volume":"338","author":"SE Valway","year":"1998","unstructured":"Valway SE, Sanchez MP, Shinnick TF, et al.: An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med 1998, 338:633\u2013639. This publication nicely describes a tuberculosis outbreak that resulted from a strain of M.Tb with unique and worrisome growth properties. The combination of meticulous epidemiology and microbiologic data make this interesting and informative reading.","journal-title":"N Engl J Med"},{"key":"14_CR41","unstructured":"Farmer P: TB resistance in developing countries. In Proceedings of the 36th Annual Meeting of the Infectious Diseases Society of America. Denver, CO. November 12\u201315, 1998."},{"key":"14_CR42","first-page":"612","volume":"2","author":"DA Mitchison","year":"1998","unstructured":"Mitchison DA. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 1998, 2:612\u2013615. The US-based rifapentine data is only available in abstracts thus far, but Professor Mitchison, who has been at the forefront of tuberculosis research for decades, provides some insight into the drama and frustration surrounding development of new antituberculous agents.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14_CR43","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1164\/ajrccm.157.5.9709072","volume":"157","author":"J Grosset","year":"1998","unstructured":"Grosset J, Lounis N, Truffot-Pernot C, et al.: Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med 1998, 157:1436\u20131440.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR44","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1164\/ajrccm.157.6.9707037","volume":"157","author":"CM Tam","year":"1998","unstructured":"Tam CM, Chan SL, Lam CW, et al.: Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med 1998, 157:1726\u20131733.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR45","unstructured":"Rifapentine Clinical Trial Group and the Division of TB Elimination: Design of USPHS TB Study 22: The rifapentine clinical trial. In Proceedings of the American Thoracic Society International Conference. San Francisco, CA. May 16\u201321, 1997."},{"key":"14_CR46","unstructured":"The USPHS Rifapentine Trial Group, Vernon A, Khan A, Bozeman L, Wang YC: Update on the U.S. Public Health Service Study 22: a trial of once weekly isoniazid (INH) & rifapentine (RPT) in continuation phase of TB treatment. In Proceedings of the American Thoracic Society International Conference. Chicago, IL. April 24\u201329, 1998."},{"key":"14_CR47","first-page":"411","volume":"1","author":"CM Tam","year":"1997","unstructured":"Tam CM, Chan SL, Lam CW, et al.: Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997, 1:411\u2013416.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14_CR48","unstructured":"Rifapentine Clinical Trial Group and the Division of TB Elimination: Rifampin-resistant relapse associated with a once-weekly continuation regimen of INH and rifapentine: relapse of HIV-TB in USPHS TB Study 22: the rifapentine clinical trial. In Global Congress of Lung Health, 29th World Conference of the International Union Against Tuberculosis and Lung Disease. Paris: October, 1997."},{"key":"14_CR49","unstructured":"Benator D, Burman W, Chaisson R, and the USPHS Study 22 Investigators: Acquired rifamycin mono-resistant tuberculosis among HIV-infected patients treated with once-weekly isoniazid and rifapentine. In 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 1\u20135, 1998."},{"key":"14_CR50","unstructured":"Daley CL: Current issues in the pathogenesis and management of HIV-related tuberculosis. AIDS Clin Rev 1997, 289\u2013321."},{"key":"14_CR51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJM199101313240503","volume":"324","author":"PM Small","year":"1991","unstructured":"Small PM, Schecter GF, Goodman PC, et al.: Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991, 324:289\u2013294.","journal-title":"N Engl J Med"},{"key":"14_CR52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(95)90519-7","volume":"345","author":"AN Ackah","year":"1995","unstructured":"Ackah AN, Coulibaly D, Digbeu H, et al.: Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d\u2019Ivoire. Lancet 1995, 345:607\u2013610.","journal-title":"Lancet"},{"key":"14_CR53","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1164\/ajrccm.155.3.9117038","volume":"155","author":"K Nakata","year":"1997","unstructured":"Nakata K, Rom WN, Honda Y, et al.: Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997, 155:996\u20131003.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1164\/ajrccm.151.1.7812542","volume":"151","author":"C Whalen","year":"1995","unstructured":"Whalen C, Horsburgh CR Jr, Hom D, et al.: Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995, 151:129\u2013135.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR55","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJM199610103351501","volume":"335","author":"SM Hammer","year":"1996","unstructured":"Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081\u20131090.","journal-title":"N Engl J Med"},{"key":"14_CR56","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","volume":"337","author":"SM Hammer","year":"1997","unstructured":"Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725\u2013733.","journal-title":"N Engl J Med"},{"key":"14_CR57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jama.280.1.78","volume":"280","author":"CC Carpenter","year":"1998","unstructured":"Carpenter CC, Fisher MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 1998, 280:78\u201386.","journal-title":"JAMA"},{"key":"14_CR58","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1086\/515030","volume":"27","author":"DM Forrest","year":"1998","unstructured":"Forrest DM, Seminari E, Hogg RS, et al.: The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis 1998, 27:1379\u20131385.","journal-title":"Clin Infect Dis"},{"key":"14_CR59","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella FJ Jr, DeLaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853\u2013860. Data is presented about recent AIDS-related death rates (through mid-1997) and is correlated with use of various intensities of antiretroviral therapy. Figure 1 is especially impressive, correlating use of protease inhibitors, starting in late 1995, with declining death rates.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"14_CR60","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","volume":"22","author":"TF Blaschke","year":"1996","unstructured":"Blaschke TF, Skinner MH: The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996, 22(Suppl 1):S15-S22.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"14_CR61","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","volume":"22","author":"CM Kunin","year":"1996","unstructured":"Kunin CM: Antimicrobial activity of rifabutin. Clin Infect Dis 1996, 22(Suppl 1):S3-S14.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"14_CR62","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1093\/clinids\/22.Supplement_1.S50","volume":"22","author":"C Grassi","year":"1996","unstructured":"Grassi C, Peona V: Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996, 22(Suppl 1):S50-S54.","journal-title":"Clin Infect Dis"},{"key":"14_CR63","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0962-8479(05)80007-3","volume":"76","author":"S Rusch-Gerdes","year":"1995","unstructured":"Rusch-Gerdes S, Mateega A, Lutalo T, et al.: A pilot study of anti-tuberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tuber Lung Dis 1995, 76:210\u2013218. The entire supplement reviews aspects of rifabutin. This article details one of the clinical trials of rifabutin for treatment of pulmonary tuberculosis in patients with HIV\/AIDS.","journal-title":"Tuber Lung Dis"},{"key":"14_CR64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0962-8479(94)90079-5","volume":"75","author":"LJ Gonzalez-Montaner","year":"1994","unstructured":"Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P, and the Rifabutin Study Group: Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuber Lung Dis 1994, 75:341\u2013347.","journal-title":"Tuber Lung Dis"},{"key":"14_CR65","first-page":"1","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","unstructured":"Centers for Disease Control and Prevention: Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998, 47:1\u201358. This new and timely CDC publication is an excellent guide to current thinking about HIV\/AIDS and tuberculosis co-infection. It addresses both treatment and prevention, recommends regimens based on what HIV therapy may be initiated, and is well referenced.","journal-title":"MMWR"},{"key":"14_CR66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/ajrccm.158.1.9712001","volume":"158","author":"M Narita","year":"1998","unstructured":"Narita M, Ashkin D, Hollender ES, Pitchenik AE: Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998, 158:157\u2013161.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR67","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00042560-199603010-00005","volume":"11","author":"JD Klausner","year":"1996","unstructured":"Klausner JD, Makonkawkeyoon S, Akarasewi P, et al.: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr 1996, 11:247\u2013257.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"14_CR68","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1086\/520275","volume":"26","author":"WM el-Sadr","year":"1998","unstructured":"el-Sadr WM, Perlman DC, Matts JP, et al.: Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998, 26:1148\u20131158.","journal-title":"Clin Infect Dis"},{"key":"14_CR69","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00002030-199510000-00011","volume":"9","author":"S Kassim","year":"1995","unstructured":"Kassim S, Sassan-Morokro M, Ackah A, et al.: Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995, 9:1185\u20131191.","journal-title":"AIDS"},{"key":"14_CR70","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJM199503233321204","volume":"332","author":"JH Perriens","year":"1995","unstructured":"Perriens JH, St.Louis ME, Mukadi YB, et al.: Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or- 12 months. N Engl J Med 1995, 332:779\u2013784.","journal-title":"N Engl J Med"},{"key":"14_CR71","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","volume":"337","author":"CC Whalen","year":"1997","unstructured":"Whalen CC, Johnson JL, Okwera A, et al.: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997, 337:801\u2013808.","journal-title":"N Engl J Med"},{"key":"14_CR72","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00002030-199707000-00006","volume":"11","author":"MP Hawken","year":"1997","unstructured":"Hawken MP, Meme HK, Elliott LC, et al.: Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997, 11:875\u2013882.","journal-title":"AIDS"},{"key":"14_CR73","unstructured":"Gordin FM, Matts JP, Miller C: A randomized trial of 2 months of rifampin (RIF) and pyrazinamide (PZA) versus 12 months of isoniazid (INH) for the prevention of tuberculosis (TB) in HIV-positive(+) patients. In 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 1\u20135, 1998."},{"key":"14_CR74","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1128\/JCM.34.8.1873-1876.1996","volume":"34","author":"GV Doern","year":"1996","unstructured":"Doern GV: Diagnostic mycobacteriology: where are we today? J Clin Microbiol 1996, 34:1873\u20131876.","journal-title":"J Clin Microbiol"},{"key":"14_CR75","first-page":"1066","volume":"115","author":"G Middlebrook","year":"1977","unstructured":"Middlebrook G, Reggiordo Z, Tigertt WD: Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir Dis 1977, 115:1066\u20131069.","journal-title":"Am Rev Respir Dis"},{"key":"14_CR76","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1164\/ajrccm.155.1.9001331","volume":"155","author":"WJ Burman","year":"1997","unstructured":"Burman WJ, Stone BL, Reves RR, et al.: The incidence of false-positive cultures for Mycobacterium tuberculosis. Am J Respir Crit Care Med 1997, 155:321\u2013326.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR77","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/JCM.36.3.684-689.1998","volume":"36","author":"F Gamboa","year":"1998","unstructured":"Gamboa F, Fernandez G, Padilla E, et al.: Comparative evaluation of initial and new versions of the Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol 1998, 36:684\u2013689. The authors compare the newest version of one of the licensed NAA tests with its forerunner and gives the reader a sense of the complications and logistics involved in NAA testing.","journal-title":"J Clin Microbiol"},{"key":"14_CR78","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1164\/ajrccm.155.5.9154896","volume":"155","author":"A Catanzaro","year":"1997","unstructured":"Catanzaro A, Davidson BL, Fujiwara PI, et al.: Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am J Respir Crit Care Med 1997, 155:1804\u20131814. A group of tuberculosis experts including clinicians, laboratorians and public health officials met to examine the place of NAA tests in clinical practice. This article summarizes the outcome of this meeting and fleshes out some of the strengths, weaknesses, and controversies surrounding the clinical utility of these tools.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR79","first-page":"443","volume":"2","author":"JA Streeton","year":"1998","unstructured":"Streeton JA, Desem N, Jones SL: Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 1998, 2:443\u2013450.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14_CR80","first-page":"441","volume":"2","author":"HM Dockrell","year":"1998","unstructured":"Dockrell HM, Weir RE: Whole blood cytokine assays: a new generation of diagnostic tests for tuberculosis? Int J Tuberc Lung Dis 1998, 2:441\u2013442.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14_CR81","first-page":"456","volume":"2","author":"I Gupta","year":"1998","unstructured":"Gupta I, Jain A, Singh NB, et al.: Role of antigen specific circulating immune complexes in diagnosis of tuberculosis. Int J Tuberc Lung Dis 1998, 2:456\u2013461.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14_CR82","first-page":"170","volume":"1","author":"S Cavalcante","year":"1997","unstructured":"Cavalcante S, Kritski AL, Ferreira MA, et al.: Association between an early humoral response to Mycobacterium tuberculosis antigens and later development of tuberculosis in human immunodeficiency virus-infected individuals. Int J Tuberc Lung Dis 1997, 1:170\u2013174.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14_CR83","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/514225","volume":"177","author":"CF Reyn von","year":"1998","unstructured":"von Reyn CF, Williams DE, Horsburgh CR Jr, et al.: Dual skin testing with Mycobacterium avium sensitin and purified protein derivative to discriminate pulmonary disease due to M. avium complex from pulmonary disease due to Mycobacterium tuberculosis. J Infect Dis 1998, 177:730\u2013736.","journal-title":"J Infect Dis"},{"key":"14_CR84","first-page":"1","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","unstructured":"Centers for Disease Control and Prevention: Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations. MMWR 1997, 46:1\u201310.","journal-title":"MMWR"},{"key":"14_CR85","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/ajrccm.155.1.9001293","volume":"155","author":"MT Hecker","year":"1997","unstructured":"Hecker MT, Johnson JL, Whalen CC, et al.: Two-step tuberculin skin testing in HIV-infected persons in Uganda. Am J Respir Crit Care Med 1997, 155:81\u201386.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR86","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2307\/30141209","volume":"18","author":"BL Mabon","year":"1997","unstructured":"Mabon BL, Ciardi B, Nouri K, Ruben FL: Skin testing for tuberculosis in university teaching hospitals \u2014 is there a problem? Infect Control Hosp Epidemiol 1997, 18:247\u2013249.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"14_CR87","unstructured":"Alexander BD, Stout JE, Reller LB, Hamilton CD: Hospital management of patients suspected of pulmonary TB in a high incidence are for MOTT [submitted for presentation]. American Thoracic Society International Conference. San Diego, CA. April 23\u201328, 1999."},{"key":"14_CR88","first-page":"25","volume":"1","author":"B Samb","year":"1997","unstructured":"Samb B, Henzel D, Daley CL, et al.: Methods for diagnosing tuberculosis among in-patients in Eastern Africa whose sputum smears are negative. Int J Tuberc Lung Dis 1997, 1:25\u201330.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14_CR89","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.109.2.420","volume":"109","author":"R Cohen","year":"1996","unstructured":"Cohen R, Muzaffar S, Capellan J, et al.: The validity of classic symptoms and chest radiographic configuration in predicting pulmonary tuberculosis. Chest 1996, 109:420\u2013423.","journal-title":"Chest"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-999-0014-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-999-0014-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-999-0014-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T09:27:53Z","timestamp":1587547673000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-999-0014-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1007\/s11908-999-0014-6","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,2]]}}}